SCHEMBL6507043

SCHEMBL6507043

CN(Cc1ccccc1)Cc1ccc(Br)nc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.50
ALDH1A1 P00352 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
KDM4E B2RXH2 1/20 0.45
CARM1 Q86X55 1/20 0.44
PRMT6 Q96LA8 1/20 0.44
PRMT8 Q9NR22 1/20 0.44
LMNA P02545 3/20 0.44
TSHR P16473 2/20 0.44
PYCR1 P32322 2/20 0.43
USP2 O75604 1/20 0.43
CYP3A4 P08684 1/20 0.43
MAOA P21397 1/20 0.43
MAOB P27338 1/20 0.43
CCR5 P51681 1/20 0.43
CHRNB2 P17787 1/20 0.42
CHRNA4 P43681 1/20 0.42
BLM P54132 1/20 0.42
BCHE P06276 1/20 0.42
ACHE P22303 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6513481 0.81 TSHR (0.56) ALDH1A1KDM4ELMNATSHRMAOB
SCHEMBL30408607 0.80 CHRNB2 (0.47) ALDH1A1TSHRCHRNB2CHRNA4
SCHEMBL743701 0.80 CHRNB2 (0.47) ALDH1A1TSHRCHRNB2CHRNA4
SCHEMBL4346767 0.79 MEN1 (0.55) HDAC1ALDH1A1SMN1; SMN2KDM4ELMNA
SCHEMBL1135398 0.78 DHFR (0.47) ALDH1A1SMN1; SMN2KDM4ELMNATSHR
SCHEMBL5255891 0.78 PDCD1 (0.44) HDAC1ALDH1A1KDM4EPYCR1
Dibemethine SCHEMBL10542007 0.77 ALDH1A1 (0.70) ALDH1A1SMN1; SMN2KDM4ECARM1PRMT6
Dibemethine SCHEMBL276863 0.77 ALDH1A1 (0.70) ALDH1A1SMN1; SMN2KDM4ECARM1PRMT6
SCHEMBL12854771 0.76 MAOA (0.45) HDAC1ALDH1A1MAOAMAOB
Dibemethine SCHEMBL2139708 0.74 ALDH1A1 (0.67) ALDH1A1SMN1; SMN2KDM4ECARM1PRMT6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273772-B2 Heteroaryl compounds as P2Y1 receptor inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-09-25 US disclosed
US-8273772-B2 Heteroaryl compounds as P2Y1 receptor inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-09-25 US disclosed
US-20100093689-A1 HETEROARYL COMPOUNDS AS P2Y1 RECEPTOR INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-04-15 US disclosed
US-20100093689-A1 HETEROARYL COMPOUNDS AS P2Y1 RECEPTOR INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-04-15 US disclosed
US-7645778-B2 Heteroaryl compounds as P2Y1 receptor inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2010-01-12 US disclosed
US-7645778-B2 Heteroaryl compounds as P2Y1 receptor inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2010-01-12 US disclosed
WO-2006078621-A9 2-PHENOXY-N- (1, 3 , 4-THIADIZOL-2-YL) PYRIDIN-3-AMINE DERIVATIVES AND RELATED COMPOUNDS AS P2Y1 RECEPTOR INHIBITORS FOR THE TREATMENT OF THROMBOEMBOLIC DISORDERS BRISTOL MYERS SQUIBB CO (US) 2008-06-19 WO disclosed
WO-2005075466-A1 SUBSTITUTED THIENYL-MERCAPTOKETONES, AND USE THEREOF FOR TREATING DISEASES ASSOCIATED WITH HISTONE DEACETYLASE ENZYMATIC ACTIVITY ARGENTA DISCOVERY LIMITED (GB) 2005-08-18 WO disclosed
WO-2005075466-A1 SUBSTITUTED THIENYL-MERCAPTOKETONES, AND USE THEREOF FOR TREATING DISEASES ASSOCIATED WITH HISTONE DEACETYLASE ENZYMATIC ACTIVITY ARGENTA DISCOVERY LIMITED (GB) 2005-08-18 WO disclosed
WO-2005040127-A1 NOVEL COMPOUNDS AS AGONIST FOR PPAR GAMMA AND PPAR ALPHA, METHOD FOR PREPARATION OF THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME LG LIFE SCIENCES LTD. (KR) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093689-A1 HETEROARYL COMPOUNDS AS P2Y1 RECEPTOR INHIBITORS P2RY1, P2RY11, P2RY2 HDAC1 4290/4885ALDH1A1 2158/4885SMN1; SMN2 3979/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.